/
LSTA
$3.39+$0.03 (+0.89%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$30.6M
9M shares
52-week range
$1.81 – $5.07
48% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.18%
Moderate
Price (6 mo)
Loading chart…
Change$-2.86
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.0M | $170.0K |
| Cost of revenue | $225.0K | $65.0K | $63.0K | $0 | $0 | $0 | $0 | $146.0K |
| Gross profit | −$225.0K | −$65.0K | −$63.0K | $0 | $0 | $0 | $1.0M | $24.0K |
| Gross margin | — | — | — | — | — | — | 100.0% | 14.1% |
| R&D | $7.6M | $13.5M | $9.3M | $17.6M | $43.5M | $12.7M | $11.3M | $7.9M |
| Operating income | −$17.0M | −$20.1M | −$19.1M | −$29.1M | −$57.6M | −$25.7M | −$22.4M | −$18.2M |
| EBITDA | −$16.8M | −$20.0M | −$19.1M | −$28.9M | −$56.6M | −$23.0M | −$20.6M | −$17.4M |
| Net income | −$16.2M | −$20.1M | −$8.2M | −$27.5M | −$54.2M | −$20.8M | −$20.0M | −$16.6M |
| Net margin | — | — | — | — | — | — | -1998.5% | -9756.5% |
| EPS (diluted) | -25.03 | -29.20 | -7.91 | -7.45 | -10.47 | -2.58 | -2.40 | -1.91 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $134725 | $-1.09 | $-1.09–$-1.09 | 1 |
| 2027 | $5M | $-1.16 | $-1.16–$-1.16 | 1 |
| 2028 | $7M | $-0.98 | $-0.98–$-0.98 | 1 |
| 2029 | $45M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.92
Price
$3.39
Implied downside
-43%
Peer comparison
Lisata Therapeutics, Inc. Common Stock
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
www.lisata.com- Employees
- 21
- IPO / List date
- Mar 1, 1999
- HQ
- BASKING RIDGE, NJ
Held by traders on TradeandTell
No one on the platform currently holds LSTA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 131,715 | $659.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2016-07-28 | 1-for-10reverse |
| 2004-09-02 | 1-for-1000reverse |
Recent trades on TradeandTell
No one on the platform has traded LSTA yet.
